Are pharma manufacturers missing a trick with pharmacovigilance?

Up to now, drug safety has been viewed primarily as a matter for compliance and risk management. Not quite a necessary evil, nor is pharmacovigilance the positive contributor to drug development success and to optimal outcomes for patients that it could and should be. That needs to change, according to Lucinda Smith, chief safety product officer at ArisGlobal. 

From original drug developers to contract manufacturers, the producers of human medicines have both a regulatory mandate as well as a duty of care to patients to ensure that their products are safe. From the drug…